• Nabis Holdings discussed the importance of cannabis legislative changes during an inaugural edition of a congressional cannabis forum in Washington, DC
• The company also announced the acquisition of a cannabis extraction and production facility in Washington state
• Through modernization and expansion, the company plans to ramp up the facility’s production capacity to 20,500 kilograms per year

Jade Green, special advisor to Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), participated in the KCSA Strategic Communications’ Inaugural Congressional Cannabis Day Forum that took place in Washington, DC on May 21, 2019. Green attended a panel discussing important legislative changes such as the federal Farm Bill and the impact that these developments have had on the cannabis industry, according to a company press release (http://ibn.fm/FdhPU).

This first-of-its-kind event provided opportunities for engagement in dialogue about cannabis and the related legislative changes occurring in the country, Green said in a news release. “Nabis will continue to be a part of the resounding voices urging congress to modernize federal cannabis laws to more effectively facilitate the growth of America’s small businesses and provide protections for consumers,” she continued.

The aim of the Congressional Cannabis Day Forum was to take a deep look at the current state and the future of the cannabis industry. The forum featured a series of panel discussions that focused on critical issues like capital markets, social justice, veterans’ issues and CBD/hemp, among others.

Nabis Holdings is a Canadian investment company that invests in high quality assets across various industries. Its primary areas of specialization include cryptocurrency, securities, real property and all aspects of the U.S. and international cannabis sectors.

Earlier in May, the company released information about a new key acquisition in the U.S. cannabis sector. On May 13, 2019, Nabis Holdings announced the purchase of several assets from PDT Technologies LLC, including an established cannabis extraction and production facility in Washington State (http://ibn.fm/LWZLx).

A definitive agreement for the purchase has already been signed. In addition to the production facility, Nabis Holdings will be purchasing extraction and production equipment, as well as the exclusive licensing rights throughout Washington for a leading brand of cannabis products called ‘Chong’s Choice’.

The PDT production facility, based in Port Townsend, specializes in high grade cannabis concentrate. Through an investment of approximately $3 million, Nabis plans to expand the facility to include new specialized equipment, two new extraction lines, a lab facility and a clean room.

Following the improvements, the facility’s capacity is expected to reach 20,500 kilograms of cannabis concentrate per year.

Finalizing the agreement with PDT will enable Nabis to expand its footprint and licensing capabilities in Washington state, Nabis CEO Shay Shnet said in a news release. The purchase of new equipment and modification of the existing facility are both in line with the company’s aggressive expansion plan.

Washington state has a relatively mature market with proven metrics. Nabis Holdings will continue evaluating new local opportunities, as well as acquisition possibilities in other limited license states.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to INNPF are available in the company’s newsroom at http://ibn.fm/INNPF

• Geyser Brands recently commenced upgrades; it anticipates R&D and processing amendments
• The facility expansion is expected to improve the company’s focus on processing quality and consumer satisfaction
• Solace Management Group recently increased its production capacity and invested in new equipment for consumer health care and pet wellness production

Geyser Brands Inc. (TSX.V: GYSR) is a leading Vancouver-based consumer health care company producing some of the world’s most popular cannabis brands and products. The company’s licensed producer (LP), Apothecary Botanicals, has received Health Canada license amendment approval to update its 7,000-square-foot facility located in Port Coquitlam, British Columbia.

This expansion, anticipated to be complete by the end of June 2019, would allow for research and development (R&D) and processing capabilities in anticipation of receiving its licensed amendments. GYSR’s R&D license is pending Health Canada’s approval of the LP facility, though the company’s facility was recently audited by Health Canada and found to be fully compliant. The company hopes to enhance its long-term success through attaining a processing license, which Geyser Brands believes will help it capitalize in the CBD wellness product market that’s predicted to be a multibillion-dollar industry (http://ibn.fm/J7DNm).

The company’s facility expansion is anticipated to include mothering and cloning rooms, along with designated areas for working with approved seed banks. A focus on processing quality will allow Geyser Brands to ensure high-CBD seed strains with consistent cannabinoid profiles, providing a reliable quality experience for consumers via its products.

Additionally, Geyser Brands recently recognized an achievement of its acquisition target, Solace Management Group Inc. GMP-compliant Solace is now in its new manufacturing facility, which is located in Coquitlam, British Columbia.

Solace hosts a dynamic portfolio of both pet and consumer health care goods, and the new facility adds to its focus on processing quality. The 7,500-square-foot construction increases production capacity by up to tenfold (http://ibn.fm/cf5Vg) and allows Solace to “develop and license new products that are either ready for production or are in various stages of development.”

In an effort to partially or fully automate processes, new equipment has also been added to the facility, including an industrial oven, advanced blending and mixing systems, rotary depositing, large-volume kettle blending, a tincture mottling system and vertical-form-fill packaging. Because of these advancements, Solace is expected to be able to meet growing market demand for its products.

In 2018, the Global Wellness Institute estimated that the global wellness economy was a $4.2 trillion market that has shown growth in recent years (http://ibn.fm/kOaHX). The teams at Geyser Brands and Solace realize the industry’s demand for product innovation and consumer satisfaction. Together, they aim to provide healthy and relevant products to a burgeoning consumer base.

“The new production facility is definitely a milestone for Solace,” Geyser Brands CEO Andreas Thatcher stated in a news release (http://ibn.fm/Mnye5). “The acquisition of Solace will provide us with a great head start as we seek to establish ourselves as a leading provider of health-focused hemp and CBD products. We have some new amazing products in the queue and being able to fulfill demand is key.”

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Long-term agreement signed with Veterans Healthcare Supply Solutions Inc. to directly distribute SofPulse devices to Veterans Administration Facilities and Department of Defense Healthcare Facilities
• Partnership with SunMED Medical Solutions, one of the premier medical equipment distributors and claim experts in the U.S., expands Endonovo’s distribution capabilities and expands ability of providers, facilities and patients to seek medical insurance reimbursement
• Holds 27 patents and numerous trademarks for several proprietary technologies and devices
• Agreement signed with national recognized hospital for use of SofPulse devices for wound healing and pain management
• Nationwide network of independent sales representatives and distributors

Endonovo Therapeutics Inc. (OTCQB: ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse Electroceutical Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.

Because SofPulse lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease
• Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease
• The company was awarded a $1 million “Part the Cloud” grant from the Alzheimer’s Association to advance XPro1595 research
• INmune recently entered a common stock purchase agreement for up to $20 million with Lincoln Park Capital

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pursuing several drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://ibn.fm/uX3hO).

INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://ibn.fm/NGhG0). Importantly, INmune Bio was recognized by the Alzheimer’s Association with a “Part the Cloud” award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease.

“2019 has marked a transformative period for INmune Bio, as the first biotech of the year to close its IPO and list on the Nasdaq,” RJ Tesi, M.D, INmune Bio’s chief executive officer, stated in a news release. “We are focused on advancing our clinical programs for the foreseeable future.”

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer’s disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer’s. A phase I clinical trial in patients with Alzheimer’s disease, supported by the Alzheimer’s Association grant, is expected to be initiated in the summer of 2019.

Upcoming catalysts for INmune Bio include advancements in several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” the body’s innate immune system to become a powerful weapon in the fight against cancer. INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.

A recently published Zacks Small-Cap Research report values INmune Bio at $19 a share. David Bautz, PhD, who wrote the report, said that Zacks (http://ibn.fm/f2ejk) is “excited by the early clinical data INmune has compiled thus far and believe that the innate immune system is a currently untapped resource for extending the lives of cancer patients.”

INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://ibn.fm/3Zu9H). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.

“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” added David Moss, CFO of INmune Bio, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.

In addition, there was an insider-led round of investment totaling approximately $4.6 million, including investments by the company’s CEO and CFO.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• The global hemp cannabidiol market is expected to top $22 billion worldwide by 2022, with CBD products comprising 25 percent of all cannabis sales
• Wildflower Brands is expanding the wellness reach of its cannabis products through a distribution pact with South African cannabis network provider Africann
• The company is also launching into Europe with a Polish network agreement through pharmaceutical distributor Two Towers

Cannabis-based wellness brand champion Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) continues to expand the reach of its holistic plant product portfolio, inking an exclusive distribution agreement for the South African natural betterment market this month.

The Wildflower Wellness brand delivers the company’s flagship lineup of full-spectrum, hemp-derived, cannabidiol-infused CBD+ branded products, which are available for use through its vaporizers, capsules, tinctures and soaps. Cannabidiol-infused wellness products are gaining mainstream acceptance. Wildflower’s products were present in the 2019 Oscar’s celebrity gift bags, at Kim Kardashian’s well-publicized CBD-focused baby shower and at the CBD beauty corner launched by “The Salon Project” at Sak’s Fifth Avenue’s flagship store.

Wildflower’s South African agreement with hemp product distributor Africann provides the company with access to “all leading pharmacy, health and wellness chains and independent pharmacy groups in South Africa,” according to a news release announcing the development (http://ibn.fm/o6yR7).

“More and more distributors are approaching us from all over the world to distribute Wildflower products,” CEO William MacLean stated in a news release. “The consistent trend is that they are looking at the US market to find CBD products to test and see what brands would fit the broadest consumer market. As global opportunities open up, Wildflower will see huge benefits from establishing itself early-on as a premium wellness brand.”

The company’s entry into the South African marketplace expands its sphere of global influence. Heavily focused on the Western seaboard of North America, Wildflower has secured distribution to more than 300 retail outlets across the United States and has a letter of intent signed in Canada to acquire City Cannabis. The company’s agreement with wholesale medicinal product distributor Two Towers enabled its entry into Poland and is serving as a gateway to the rest of Europe (http://ibn.fm/FSkKQ).

Analysts at The Brightfield Group forecast that the European CBD product market is set to explode, with 400 percent growth expected through 2023 (http://ibn.fm/VdvSW). The research firm predicts that the hemp CBD market will top $22 billion globally by 2022 (http://ibn.fm/7okmx) and that CBD products will comprise 25 percent of all cannabis sales.

Wildflower recently announced that it logged more than $1.4 million in sales during its most recent quarterly filing, marking the tenth consecutive quarter of growing revenue figures (http://ibn.fm/3oh7D).

The company has also established a partnering agreement with cannabis educator HelloMD to provide information and products for medical cannabis patients across the United States (http://ibn.fm/xNq1R).

For more information, visit the company’s website at www.WildflowerBrands.co

NOTE TO INVESTORS: The latest news and updates relating to WLDFF are available in the company’s newsroom at http://ibn.fm/WLDFF

• Genprex, a clinical stage gene therapy company, will be utilizing the services of a leading pharmaceutical branding agency to oversee the naming process of its lead drug candidate, Oncoprex
• Addison Whitney has over 28 years of experience in the market, guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps involved in the name approval process
• Oncoprex is an innovative immunogene therapy targeting non-small cell lung cancer

Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, recently reported that it has retained the services of leading pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://ibn.fm/ci3KJ).

The move will enable Genprex to pursue the commercialization of Oncoprex immunogene therapy, which is currently in development and undergoing a clinical trial for the treatment of non-small cell lung cancer (NCSLC).

Addison Whitney will draw from its 28 years of market experience to oversee the proprietary and non-proprietary naming process for Genprex’s leading drug candidate.

Addison Whitney has a proven track record of branding success within the pharmaceutical market. It enables clients to achieve growth through both brand differentiation and creative naming practices. Its most recent successes include guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps needed for name approval.

According to Genprex Chairman and CEO Rodney Varner, retaining the services of Addison Whitney is an important step in bringing Oncoprex to market. Obtaining regulatory approval for the proprietary and non-proprietary drug names is one of the essentials for securing market approval, he explained. Varner said that he believes that Addison Whitney has an excellent reputation when it comes to securing such name approvals.

Currently, Genprex is carrying out a phase I/II clinical trial of Oncoprex in combination with erlotinib, treating NSCLC. Additionally, preclinical studies are underway to evaluate the effectiveness of Oncoprex in combination with immunotherapies.

Oncoprex works by interrupting the cell signaling pathways that contribute to the replication of cancer cells. It also stimulates the natural immune response against cancer. Oncoprex consists of TUSC2 – a tumor suppressor gene – encapsulated in a lipid nanoparticle. When injected intravenously, it specifically targets cancer cells, where the tumor suppressor gene is taken up and expressed in a protein that restores some of the defective gene functions arising in cancer cells.

Lung cancer is the leading cause of cancer deaths across the world, killing more people than breast, colon, kidney, liver, prostate and skin cancers combined. While newly diagnosed lung cancer cases have remained at steady annual levels among men, an increase of over 40 percent in new diagnoses is expected in women by 2030 (http://ibn.fm/p7BVD). In comparison, the global standardized breast cancer mortality rate among women is expected to go down nine percent within the same period.

Companies like Genprex are leading the way in identifying, researching and developing innovative treatment options. Genprex holds a portfolio of more than 30 patents for its platform technologies. In addition, it’s currently working on pinpointing the biomarkers that will help the selection of patients who will benefit the most from the Genprex treatments.

For more information, visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Beyond Meat’s financial results will be announced during a conference call scheduled for June 6
• A live webcast will also be available via the company’s official website for investors interested in the financial information
• Beyond Meat’s portfolio of plant-based foods that replicate the taste and texture of meat has grown in popularity since the company’s launch in 2009, and its products are now available at more than 30,000 retail locations around the world

Beyond Meat Inc. (NASDAQ: BYND), a leading provider of plant-based meat substitute products, recently announced that its financial results for the first quarter of 2019 will be presented live on June 6.

A conference call will be held at 4:30 pm ET, after markets close. All investors interested in participating can dial 866-221-1171 from the U.S., or 270-215-9602 internationally. Two hours after the end of the conference call, a telephone replay will become available, Beyond Meat said in a press release.

The company has also announced that a simultaneous webcast will be taking place via Beyond Meat’s website. An archive of the webcast will be made available for a period of 30 days following the end of the conference call.

Beyond Meat currently ranks as one of the fastest-growing food companies in the U.S. Its portfolio consists of plant-based meat alternatives. Through innovative practices, Beyond Meat gives consumers an opportunity to experience the taste and texture of meat while enjoying the nutritional benefits of plant-based foods.

Founded in 2009, Beyond Meat operates under the slogan ‘Eat What You Love’. The company is committed to giving its clients a tasty experience while also enabling food production that is healthy, sustainable and cruelty-free.

Plant-based meat substitute products are a healthy alternative to red meat, which has been linked to several diseases (http://ibn.fm/YILX7), while also offering a positive impact on climate change by consuming fewer resources in their manufacturing processes (http://ibn.fm/QUrpf).

As a result, the global meat substitute market has grown exponentially and is set to reach $7.5 billion by 2025, according to Allied Market Research (http://ibn.fm/SSXRm). Beyond Meat aims to be at the forefront of this growth and remain a key player in this growing industry by providing delicious and sustainable meat substitutes.

Beyond Meat’s fresh and frozen products are available at more than 30,000 retail and food service locations throughout the world.

For more information, visit the company’s website at www.BeyondMeat.com

• INmune Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on February 4, 2019
• Public clinical-stage immunology company with programs in oncology and neurodegenerative disease
• INmune Bio targets large markets with unsolved problems such as resistance to checkpoint inhibitor therapy, a fast-growing oncology market segment; MRD, the cause of cancer relapse; and neuroinflammation as a cause of Alzheimer’s disease
• Receiver of “Part the Cloud” $1 million grant awarded by Alzheimer’s Association
• Experienced leadership with extensive experience in the targeted fields of clinical research and drug development
• Intellectual property with multiple filings in process for INB03/XPro1595 and INKmune
• Insider led round at $9 per share for approximately $4.6 million in May

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient’s innate immune system to fight disease. Drug candidates INKmune and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach to promote the body’s innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a “Part the Cloud” award from the Alzheimer’s Association in 2018 which included a $1 million grant to advance INmune Bio’s XPro1595 drug candidate.

INmune Bio’s product pipeline targets three segments of concern:

• Alzheimer’s disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer’s as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
• Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer (“NK”) cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
• Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient’s resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease (“MRD”).

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells (“MDSC”) which can produce an immunosuppressive shield that prevents a patient’s own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer’s disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer’s.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer’s disease who have neuroinflammation. The trial is supported by a $1 million “Part the Cloud” grant from the Alzheimer’s Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer’s disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss, co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor’s degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company’s formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum’s research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer’s Association. He received his Ph.D. in neuroscience from Binghamton University.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

• Sproutly is a licensed producer with exclusive rights to Infusion Biosciences’ groundbreaking Aqueous Phytorecovery Process (“APP”) technology for naturally water-soluble cannabinoids
• The Canadian cannabis beverage market is estimated to exceed $4 billion by 2022
• SRUTF executives were tapped to present APP technology at key cannabis conferences

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) is rapidly gaining positive exposure in the cannabis space as the company presents its proprietary APP technological platform at numerous key cannabis conferences in the U.S. and Canada. Sproutly executives most recently shared details of the APP process at the Canaccord Genuity Third Annual Cannabis Conference and at the Cannastocks 2019 Q1 Investor Conference, both in New York City (http://ibn.fm/VfnkU).

Sproutly is also slated to be a featured exhibitor at the Lift & Co Expo on June 6-9 at the Metro Toronto Convention Center in Toronto, Canada. Following this event, Chief Science Officer Dr. Arup Sen will present at the Cannabis Drinks Expo at the South San Francisco Conference Center in San Francisco on July 25, 2019 (http://ibn.fm/J8vH1).

Sproutly acquired Infusion Biosciences and its patent-pending APP technology, which extracts water-soluble forms of cannabinoids for inclusion in beverages and edibles, in August 2018. The deal came with exclusive rights to the APP technology in Canada, Australia, Israel, Jamaica and the EU. Sproutly CEO Keith Dolo described the company’s premium offering, Infuz2O, as “the world’s first and only, truly water-soluble cannabis solution” for formulation into beverages.

“APP technology is a low-cost, gentle method to produce Infuz2O, a groundbreaking discovery that delivers the total effects of the strain of cannabis from which it is made; on-set effects start within approximately 5 minutes and dissipate within approximately 90 minutes,” Dolo stated in an August 2018 news release (http://ibn.fm/klQie).

Infuz2O offers predictable effects that are comparable to smoking and vaping, while also providing an odorless, smokeless and versatile product with precise dosing. While current products on the market can have lingering effects lasting anywhere from four hours to two days, effects from Sproutly’s premium product lasts between 60 and 90 minutes. APP technology is also used in the production of Bio Natural Oils, which deliver the full-spectrum of cannabinoids and terpenes of the strain from which they are made, thus empowering consumers to enjoy the experience of their strains of choice in an edible form (http://ibn.fm/v7jV1).

A joint venture between Sproutly and OCC Holdings Ltd., an affiliate of Moosehead Breweries Limited, one of Canada’s oldest and largest independent breweries, is another positive sign that the cannabis consumable market is ready to explode. The joint venture’s product line will utilize Sproutly’s proprietary Infuz2O water-soluble cannabis formulation to create a truly natural cannabis beverage experience that serves as an alternative to alcoholic products, as the company stated in a news release (http://ibn.fm/1vpJe).

“This partnership with Moosehead marks an important milestone in Sproutly’s mission of delivering a safe and consistent whole plant experience from cannabis, with a lead position in the beverage market,” Dolo stated in a news release. “We have developed a relationship with Moosehead built on trust and our shared vision of creating safe, responsible and high-quality cannabis beverages and we look forward to making this a reality for Canadian consumers.”

ArcView Market Research and BDS Analytics project that consumers in the United States and Canada will spend more than $4 billion on cannabis edibles by 2020 (http://ibn.fm/yTfQ8). “Legal cannabis-derived edible products, from candy and chocolate to infused beverages, is a sector worth watching over the next few years,” the report stated.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer
• Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer
• Clinical trials so far have yielded encouraging data regarding the efficacy and safety of the company’s product candidate, Oncoprex

Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help patients with various malignancies.

Gene therapy refers to the therapeutic delivery of DNA or RNA to the cells of a patient for the purpose of treating a disease. It was first conceptualized in 1972, and some of the first successful gene therapy trials took place in the 1990s (http://ibn.fm/ioJWo).

Today, Genprex is working on an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (NSCLC). The company’s initial product candidate is called Oncoprex immunogene therapy, and it encapsulates a tumor suppressor gene (TUSC2) that is delivered through cholesterol nanoparticles.

Oncoprex is administered intravenously. According to Genprex CEO Rodney Varner, Oncoprex allows a systemic and targeted approach toward the treatment of NSCLC, because the nanoparticles are attracted to the cancer cells like a magnet.

Once Oncoprex reaches the cancer cells, TUSC2 is expressed into a protein that restores some of the defective gene functions arising in cancer cells, and the nanoparticles are taken up at a rate that’s up to 25-times higher than in the case of normal cells.

Research suggests that Oncoprex is synergistic with targeted and immunotherapies, and research has also shown that Oncoprex delivers results in several ways. It interrupts the proliferation of cancer cells, helps cancer cell death and modulates the immune response against cancer cells. In addition, Oncoprex blocks mechanisms that can contribute to drug resistance and has demonstrated minimal side effects compared to other lung cancer drugs.

Currently, Genprex holds more than 30 patents for its platform technologies. The company has also recruited renowned scientists, forming a powerful team that features some of the brightest minds in biotech, oncology and clinical research.

Genprex is now conducting the second phase of a phase I/II clinical trial. It also plans to expand its pipeline through the addition of a new clinical study that evaluates the effectiveness of Oncoprex in combination with a checkpoint inhibitor for the treatment of NSCLC.

NSCLC is the most common type of lung cancer. It accounts for approximately 85 percent of all lung cancer cases and, despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://ibn.fm/zQh71).

Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of effectiveness. Gene therapy could be the one innovative development that will contribute to curing what’s currently incurable, and companies like Genprex are spearheading these efforts.

For more information, visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX